The results of a productive collaboration between Domainex and Oxford University have been published in a recent Nature Communications paper titled "Small molecule inhibitors of RAS-effector protein interactions derived using an intrace
20th December 2018
20th September 2018
Cambridge, UK, 20th September 2018 / Domainex Ltd, a privately-owned drug research services company, is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018.
30th April 2018
Cambridge, UK, 30th April 2018 / Domainex Ltd, a privately-owned drug discovery services company, is proud to announce its inclusion in the second annual top 1000 list of Europe’s fastest growing companies, published by the Financial Times. Th
23rd January 2018
12th September 2017
Cambridge, UK and Stevenage, UK – 12 September 2017 - Domainex and Auspherix have announced new data from their collaboration to develop novel candidate drugs to tackle the growing thr
14th June 2017
Cambridge, UK, 14 June 2017/ Domainex Ltd.
17th May 2017
Domainex signs multi-year agreement with Dotmatics – a leading provider of scientific informatics – to streamline its integrated drug discovery services
7th March 2017
Domainex launched its fragment screening service, FragmentBuilder, and is the first CRO in the UK to offer MicroScale Thermophoresis (MST) as part of drug discovery services.
15th December 2016
Domainex has purchased a Monolith NT. Automated instrument, using MicroScale Thermophoresis (MST) technology for high-throughput fragment-based drug discovery.
17th November 2016
Sir Simon Campbell opened the Domainex Medicines Research Centre, which will double the laboratory space available to the company’s growing team of scientists.